ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

formoterol

Also written as “Formoterol Fumarate”, “budesonide/formoterol” and “Formoterol”.

Its studies are mostly in Asthma · Pulmonary Disease, Chronic Obstructive · Bronchitis, Chronic · Asthma, Exercise-Induced, led by 18 companies.

Drug pageFormoterol: every studyMany companies study it; this page follows only the 137 they lead. All 190 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jan 4, 2006137 company-led studies, 2 open or runningNext primary completion: May 31, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZenecaits history only632 open or runningphase 4since Jan 4, 2006Sep 13, 2005May 31, 2027phase 4 · NCT07073950
Chiesi Farmaceuticiits history only200 open or runningphase 4since Nov 29, 2010Oct 30, 2006none ahead
Viatris160 open or runningphase 4since Nov 29, 2011Sep 13, 2005none ahead
Novartisits history only60 open or runningphase 4since Jul 26, 2005Jul 26, 2005none ahead
Sumitomo Pharmaits history only60 open or runningphase 4since Jan 17, 2007Jul 8, 2003none ahead
SkyePharmaits history only50 open or runningphase 3since Oct 27, 2006Oct 27, 2006none ahead
Eurofarma Laboratoriosits history only30 open or runningphase 3since Oct 23, 2009Oct 23, 2009none ahead
Mundipharmaits history only30 open or runningphase 4since Jun 15, 2015Oct 14, 2009none ahead
Ache Laboratorios Farmaceuticosits history only20 open or runningphase 3since Mar 9, 2011Mar 9, 2011none ahead
Boehringer Ingelheimits history only20 open or runningphase 2since Sep 11, 2014Sep 11, 2014none ahead

Also a collaborator on its studies: Parexel, CISCRP, eResearchTechnology, Menarini Group, Integrated Therapeutics Group and Pacira BioSciences.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Viatris only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 13, 2005First studies: 2 phase 3 studies in Pulmonary Disease, Chronic ObstructiveFirst studyNCT00215449, NCT00215436
  2. Sep 13, 20056 phase 2 studiesNCT00215423, NCT00215410, NCT00215397 and 3 more
  3. Jan 19, 2006Phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT00280371 · 345 enrolled · United States
  4. Mar 27, 2006Phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT00308191 · 128 enrolled · United States
  5. Nov 21, 2006Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT00403286 · 457 enrolled · United States
  6. Jul 24, 2007Phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT00507234 · 128 enrolled · United States
  7. Oct 16, 2008Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT00774761 · 97 enrolled · United States
  8. Apr 27, 2010Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT01113593 · 45 enrolled · United States
  9. Jul 21, 2010Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT01168310 · 468 enrolled · United States
  10. Nov 29, 2011Phase 4 study in Pulmonary Disease, Chronic ObstructiveNCT01488019 · 1,071 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 16 Viatris leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01488019Pulmonary Disease, Chronic Obstructive · United States4CompletedJan 20161,071
NCT01168310Pulmonary Disease, Chronic Obstructive · United States2CompletedAug 2010468
NCT01113593Pulmonary Disease, Chronic Obstructive · United States2CompletedMay 201045
NCT00774761Pulmonary Disease, Chronic Obstructive · United States2CompletedApr 200997
NCT00507234Pulmonary Disease, Chronic Obstructive · United States3CompletedOct 2007128
NCT00403286Pulmonary Disease, Chronic Obstructive · United States2CompletedMay 2007457
NCT00308191Pulmonary Disease, Chronic Obstructive · United States3CompletedMay 2006128
NCT00280371Pulmonary Disease, Chronic Obstructive · United States3CompletedJul 2006345
NCT00215449Pulmonary Disease, Chronic Obstructive · United States3CompletedDec 2005690
NCT00215436Pulmonary Disease, Chronic Obstructive · United States3CompletedSep 2005345
NCT00215423Pulmonary Disease, Chronic Obstructive · United States2CompletedDec 200349
NCT00215410Asthma · United States2CompletedOct 200336
NCT00215397Asthma · United States2CompletedFeb 200316
NCT00215384Pulmonary Disease, Chronic Obstructive · United States2CompletedApr 200335
NCT00215371Asthma · United States2CompletedOct 200232
NCT00215358Asthma · United States2CompletedOct 200232

How it is read

Names in the registry

  • “Formoterol Fumarate”, 14 entries
  • “budesonide/formoterol”, 10 entries
  • “Formoterol”, 9 entries
  • “Fluticasone Propionate/Formoterol Fumarate”, 9 entries
  • “BGF MDI 320/14.4/9.6 μg”, 6 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.